Safety and Efficacy of Allergen Immunotherapy in Patients with HIV and Allergic Rhinitis: Facts and Fiction

Alam, Saima; Calderón, Moisés A.

doi:10.1007/s40521-014-0039-4

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical reports of the safety of AIT under a current viral infection are scarce in general. In a comprehensive article, the limited literature of AIT in HIV patients with allergic diseases has been reviewed and found a lack of sufficient evidence for or against the application of AIT in HIV patients and further investigations collaborated by allergists together with HIV experts has been requested 57 . In one trial, clinical effects and safety of SLIT with grass tablets have been investigated in 13 HIV‐positive and grass pollen‐allergic patients with current antiretroviral therapy (HAART) 37 .…”

Section: Discussionmentioning

confidence: 99%

“…In a comprehensive article, the limited literature of AIT in HIV patients with allergic diseases has been reviewed and found a lack of sufficient evidence for or against the application of AIT in HIV patients and further investigations collaborated by allergists together with HIV experts has been requested. 57 In one trial, clinical effects and safety of SLIT with grass tablets have been investigated in 13 HIV-positive and grass pollenallergic patients with current antiretroviral therapy (HAART). 37 The clinical outcomes for allergic symptoms and quality of life improved significantly compared with nine control patients, whereas no alteration of HIV viral load or CD4-positive T cells was found.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

COVID‐19 pandemic and allergen immunotherapy—an EAACI survey

Pfaar

Agache

Bonini

et al. 2021

Allergy

View full text Add to dashboard Cite

Background As in many fields of medical care, the coronavirus disease 2019 (COVID‐19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Method Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group (IT IG) set‐up a web‐based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID‐19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID‐19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Conclusions This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID‐19 pandemic and gave no concerns regarding reduced tolerability under real‐life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long‐lasting negative impact on the clinical care of allergic patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%